Clinical Trials · NCT07310563
A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Amgen
- Enrollment
- 59
- Start date
- Dec 2024
- Locations
- 1 site, United States
- Primary endpoint
- Maximum Observed Plasma Concentration (Cmax) of AMG 133